Data from a real-world retrospective analysis suggests that, for those on multiple daily injections (MDI) of insulin, Bigfoot Unity has the potential to provide rapid and durable glycemic control improvements.
Milpitas, California–based Bigfoot presented the real-world data from its late-breaking abstract at the American Diabetes Association (ADA) 82nd Annual Scientific Sessions in New Orleans.
Get the full story at our sister site, Drug Delivery Business News.